Alps Group Inc and Globalink Investment Inc have successfully completed their business combination, with Alps Group continuing as the surviving publicly traded entity. The transaction was approved by Globalink’s stockholders and is expected to have an enterprise value of approximately US$1.6 billion. Dr. Tham Seng Kong will serve as the CEO and Chairman of Alps Group, which will commence trading on the Nasdaq Stock Market under the symbol “ALPS” on October 31, 2025. The company aims to deliver predictive, preventive, and precision medicine to patients worldwide.

Alps Group Inc, a biotechnology research and healthcare platform, is now listed on Nasdaq under the ticker symbol “ALPS,” following a successful business combination with Globalink Investment Inc. The company’s mission is to redefine the future of healthcare by making advanced therapies accessible and affordable globally. Dr. Tham Seng Kong, the CEO of Alps Group, highlighted the company’s commitment to delivering transformative healthcare solutions and fostering collaboration within the biotech industry through initiatives like the BioValley hub in Malaysia. The company also entered into subscription agreements with investors to support its growth strategy and working capital requirements.

Read more at GlobeNewswire: Alps Announces Closing of Business Combination with